Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4074044 | 0.75 | MAP4K1 (0.30) | — | |
| SCHEMBL8828745 | 0.74 | ALDH1A1 (0.65) | ALDH1A1MAPK1SMN1; SMN2POLBGFER | |
| SCHEMBL7749289 | 0.73 | SMN1; SMN2 (0.39) | ALDH1A1MAPK1SMN1; SMN2POLBHTT | |
| SCHEMBL24984062 | 0.71 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL4082477 | 0.70 | ALDH1A1 (0.39) | ALDH1A1MAPK1SMN1; SMN2POLBTSHR | |
| SCHEMBL1989330 | 0.70 | ALDH1A1 (0.50) | ALDH1A1MAPK1SMN1; SMN2POLBKMT2A | |
| SCHEMBL1724048 | 0.70 | NFKB1 (0.44) | ALDH1A1SMN1; SMN2HTTKMT2ACNR1 | |
| SCHEMBL30986414 | 0.69 | GFER (0.35) | ALDH1A1MAPK1SMN1; SMN2POLBGFER | |
| Hydrochloric Acid SCHEMBL10581422 | 0.69 | ALDH1A1 (0.48) | ALDH1A1MAPK1SMN1; SMN2POLBKMT2A | |
| SCHEMBL9135606 | 0.69 | ALDH1A1 (0.35) | ALDH1A1MAPK1SMN1; SMN2POLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482355-B2 | Asthma, antiallergens; rheumatoid arthritis and atherosclerosis; 2-(Benzylthio)-6-{[(1R)-2-hydroxy-1-methylethyl]amino}-4-pyrimidinol | ASTRAZENECA AB (SE) | 2009-01-27 | — | — | US | disclosed |
| EP-1539713-B1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2007-12-19 | — | — | EP | disclosed |
| US-20060004030-A1 | Pyrimidine derivatives as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2006-01-05 | — | — | US | disclosed |
| EP-1539713-A1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Astrazeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004018435-A1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004030-A1 | Pyrimidine derivatives as modulators of chemokine receptor activity | CXCR2, CXCR1, ACKR3 | ALDH1A1 619/4885MAPK1 1430/4885SMN1; SMN2 2937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.